JP2011506422A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011506422A5 JP2011506422A5 JP2010537542A JP2010537542A JP2011506422A5 JP 2011506422 A5 JP2011506422 A5 JP 2011506422A5 JP 2010537542 A JP2010537542 A JP 2010537542A JP 2010537542 A JP2010537542 A JP 2010537542A JP 2011506422 A5 JP2011506422 A5 JP 2011506422A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- variable region
- chain variable
- autoimmune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000539 amino acid group Chemical group 0.000 claims description 27
- 210000004408 hybridoma Anatomy 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 230000001404 mediated effect Effects 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
- 239000012636 effector Substances 0.000 claims description 6
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 4
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 4
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 4
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 4
- 208000024908 graft versus host disease Diseases 0.000 claims description 4
- 201000005962 mycosis fungoides Diseases 0.000 claims description 4
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 230000003325 follicular Effects 0.000 claims description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 3
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 2
- 206010071576 Autoimmune aplastic anaemia Diseases 0.000 claims description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 2
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010011878 Deafness Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010013554 Diverticulum Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 2
- 206010021263 IgA nephropathy Diseases 0.000 claims description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
- 201000002481 Myositis Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 201000011152 Pemphigus Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 2
- 201000003278 cryoglobulinemia Diseases 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 230000010370 hearing loss Effects 0.000 claims description 2
- 231100000888 hearing loss Toxicity 0.000 claims description 2
- 208000016354 hearing loss disease Diseases 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 206010063344 microscopic polyangiitis Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010057645 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012305 Demyelination Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 201000004982 autoimmune uveitis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000000813 microbial effect Effects 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010003253 Arthritis enteropathic Diseases 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 102000004527 Interleukin-21 Receptors Human genes 0.000 description 1
- 108010017411 Interleukin-21 Receptors Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1232907P | 2007-12-07 | 2007-12-07 | |
| US61/012,329 | 2007-12-07 | ||
| PCT/IB2008/005011 WO2010055366A2 (en) | 2007-12-07 | 2008-12-08 | Anti-human il-21 monoclonal antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014036592A Division JP5848384B2 (ja) | 2007-12-07 | 2014-02-27 | 抗ヒトｉｌ−２１モノクローナル抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011506422A JP2011506422A (ja) | 2011-03-03 |
| JP2011506422A5 true JP2011506422A5 (cg-RX-API-DMAC7.html) | 2011-12-01 |
| JP5745274B2 JP5745274B2 (ja) | 2015-07-08 |
Family
ID=40899470
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010537542A Active JP5745274B2 (ja) | 2007-12-07 | 2008-12-08 | 抗ヒトｉｌ−２１モノクローナル抗体 |
| JP2014036592A Active JP5848384B2 (ja) | 2007-12-07 | 2014-02-27 | 抗ヒトｉｌ−２１モノクローナル抗体 |
| JP2015230496A Active JP6027668B2 (ja) | 2007-12-07 | 2015-11-26 | 抗ヒトｉｌ−２１モノクローナル抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014036592A Active JP5848384B2 (ja) | 2007-12-07 | 2014-02-27 | 抗ヒトｉｌ−２１モノクローナル抗体 |
| JP2015230496A Active JP6027668B2 (ja) | 2007-12-07 | 2015-11-26 | 抗ヒトｉｌ−２１モノクローナル抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US7883700B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP2426146B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP5745274B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR101591316B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN102027011B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008364115B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0821168B8 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2910933C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2217268T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2572231T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE027828T2 (cg-RX-API-DMAC7.html) |
| IL (2) | IL205976A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2010006181A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2217268T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2217268T (cg-RX-API-DMAC7.html) |
| RU (1) | RU2504552C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010055366A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201004046B (cg-RX-API-DMAC7.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1963369T3 (pl) | 2005-11-28 | 2013-10-31 | Zymogenetics Inc | Antagoniści IL-21 |
| EP2426146B1 (en) | 2007-12-07 | 2016-02-17 | ZymoGenetics, Inc. | Anti-human IL-21 monoclonal antibodies |
| US20130224109A1 (en) * | 2010-07-20 | 2013-08-29 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods featuring il-6 and il-21 antagonists |
| JP2014506259A (ja) * | 2011-01-17 | 2014-03-13 | ノヴォ ノルディスク アー／エス | Ｉｌ−２１リガンド |
| JP2014518198A (ja) * | 2011-05-31 | 2014-07-28 | ノヴォ ノルディスク アー／エス | Ｉｌ−２１のエピトープおよびｉｌ−２１リガンド |
| HRP20180776T1 (hr) * | 2011-10-19 | 2018-08-10 | Morphosys Ag | Antagonisti il17c za liječenje upalnih poremećaja |
| EP2746293A1 (en) | 2012-12-21 | 2014-06-25 | Novo Nordisk A/S | Anti-IL21 antibodies for use in the treatment of cardiovascular diseases |
| US20140178395A1 (en) * | 2012-12-21 | 2014-06-26 | Novo Nordisk A/S | Treatment of nephropathy |
| WO2014205501A1 (en) | 2013-06-27 | 2014-12-31 | Monash University | Il-21 binding proteins and uses thereof |
| CN103487572B (zh) * | 2013-10-08 | 2017-03-29 | 北京大学人民医院 | 滤泡辅助性T淋巴细胞(Tfh)在自身免疫性疾病病情预警中的应用 |
| CN104721820A (zh) * | 2013-12-24 | 2015-06-24 | 信达生物制药(苏州)有限公司 | 双特异性单克隆抗体在治疗葡萄膜炎中的用途 |
| WO2015132241A1 (en) * | 2014-03-03 | 2015-09-11 | Novo Nordisk A/S | Treatment of inflammatory diseases |
| AR099625A1 (es) | 2014-03-21 | 2016-08-03 | Lilly Co Eli | Anticuerpos de il-21 |
| LT3128997T (lt) * | 2014-04-08 | 2020-10-12 | Boston Pharmaceuticals Inc. | Surišančios molekulės, specifinės il-21, ir jų panaudojimas |
| JP6672175B2 (ja) * | 2014-05-07 | 2020-03-25 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１及び抗ｉｌ−２１を使用した１型糖尿病の治療 |
| PT3139948T (pt) * | 2014-05-07 | 2020-05-22 | Novo Nordisk As | Tratamento de diabetes usando glp-1 e anti-il-21 |
| RU2609627C2 (ru) | 2014-09-26 | 2017-02-02 | Закрытое Акционерное Общество "Биокад" | Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh |
| CN107249633A (zh) * | 2014-12-19 | 2017-10-13 | 迈博太科公司 | 用于抑制il‑21介导的人细胞活化的组合物、试剂盒和方法 |
| WO2016094962A1 (en) | 2014-12-19 | 2016-06-23 | Monash University | Il-21 antibodies |
| JP7010833B2 (ja) * | 2016-03-31 | 2022-02-10 | イーライ リリー アンド カンパニー | Ｉｌ－２１抗体及びその使用 |
| WO2018045273A2 (en) * | 2016-09-02 | 2018-03-08 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating neoplasias |
| JP6952295B2 (ja) * | 2016-09-09 | 2021-10-20 | 国立大学法人金沢大学 | ヒト抗ｈｌａモノクローナル抗体の作製方法 |
| CR20200099A (es) | 2017-08-03 | 2020-07-24 | Amgen Inc | Muteínas de interleucina 21 y métodos de tratamiento |
| TW201930344A (zh) | 2018-01-12 | 2019-08-01 | 美商安進公司 | 抗ｐｄ-１抗體及治療方法 |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| WO2022013221A1 (en) * | 2020-07-13 | 2022-01-20 | Transgene | Treatment of immune depression |
| CN118370816A (zh) * | 2024-03-22 | 2024-07-23 | 中日友好医院(中日友好临床医学研究所) | Il-2/抗il-2抗体免疫复合物的应用 |
| WO2025257327A1 (en) | 2024-06-13 | 2025-12-18 | Almirall, S.A. | Therapeutic approaches for the management of hidradenitis suppurativa |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US7198789B2 (en) | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
| US6057128A (en) | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
| US20010023070A1 (en) * | 1998-05-29 | 2001-09-20 | Reinhard Ebner | Interleukins-21 and 22 |
| EE05627B1 (et) * | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| CN102406937A (zh) | 1999-03-09 | 2012-04-11 | 津莫吉尼蒂克斯公司 | 新的细胞因子zalpha11配体 |
| DE60125543T2 (de) | 2000-04-05 | 2007-10-04 | Zymogenetics, Inc., Seattle | Löslicher zytokinrezeptor zalpha11 |
| AU2001271786A1 (en) | 2000-06-30 | 2002-01-14 | Zymogenetics Inc. | Interferon-like protein zcyto21 |
| ES2335861T3 (es) | 2000-09-08 | 2010-04-06 | Universitat Zurich | Grupos de proteinas repetitivas que comprenden modulos repetitivos. |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| MXPA03010687A (es) | 2001-05-24 | 2004-07-01 | Zymogentetics Inc | Proteinas de fusion de taci-inmunoglobulina. |
| DK1451322T3 (da) | 2001-11-05 | 2010-02-01 | Zymogenetics Inc | Il-21-antagonister |
| US20040028665A1 (en) | 2002-01-08 | 2004-02-12 | Garner Bryan E. | Compositions and methods for inhibiting pathogenic growth |
| WO2003087320A2 (en) | 2002-04-09 | 2003-10-23 | Beth Israel Deaconess Medical Center, Inc. | Antagonists of il-21 and modulation of il-21-mediated t cell responses |
| US20040016010A1 (en) | 2002-04-17 | 2004-01-22 | Marion Kasaian | IL-21 receptor knockout animal and methods of use thereof |
| PT1531850E (pt) | 2002-06-07 | 2012-05-07 | Zymogenetics Inc | Utilização de il-21 e anticorpo monoclonal para tratar cancros sólidos |
| ZA200500480B (en) | 2002-07-15 | 2006-10-25 | Wyeth Corp | Methods and compositions for modulating T helper (TH) cell development and function |
| WO2004032857A2 (en) | 2002-10-08 | 2004-04-22 | Immunomedics, Inc. | Antibody therapy |
| US20070092485A1 (en) * | 2002-11-15 | 2007-04-26 | Zymogenetics, Inc. | Cytokine zalpha11 ligand |
| DK1573006T3 (da) | 2002-12-13 | 2010-03-22 | Zymogenetics Inc | Fremstilling af IL-21 i prokaryotiske værter |
| WO2004056392A1 (en) | 2002-12-23 | 2004-07-08 | Innate Pharma | Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same |
| WO2004083249A2 (en) * | 2003-03-14 | 2004-09-30 | Wyeth | Antibodies against human il-21 receptor and uses therefor |
| ZA200507235B (en) * | 2003-03-21 | 2007-03-28 | Wyeth Corp | Treating immunological disorders using agonists of interleukin-21/interleukin-21 receptor |
| MXPA06004199A (es) | 2003-10-17 | 2006-06-28 | Novo Nordisk As | Terapia en combinacion. |
| JP4471721B2 (ja) | 2004-04-20 | 2010-06-02 | 独立行政法人産業技術総合研究所 | 抗インターロイキン２１受容体（ｉｌ−２１ｒ）抗体および本抗体を産生するハイブリドーマ |
| AU2005244942A1 (en) | 2004-05-19 | 2005-12-01 | Wyeth | Modulation of immunoglobulin production and atopic disorders |
| US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| RU2007102287A (ru) | 2004-08-05 | 2008-09-10 | Вайет (Us) | Антагонисты активности рецептора интерлейкина-21 |
| KR100654124B1 (ko) | 2004-11-18 | 2006-12-08 | 주식회사 하이닉스반도체 | 벙커 디펙트를 억제할 수 있는 반도체 소자 제조 방법 |
| ITRM20040586A1 (it) * | 2004-11-29 | 2005-02-28 | Giuliani Spa | Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico. |
| WO2006105538A2 (en) * | 2005-03-31 | 2006-10-05 | Centocor, Inc. | Methods and compositions for treating il-21 related pathologies |
| DK200501310A (da) * | 2005-09-21 | 2005-10-01 | Novo Nordisk As | The invention relates to the treatment or prevention of autoimmune diseases and latent autoimmune diabetes in the adults |
| US7592427B2 (en) * | 2005-11-28 | 2009-09-22 | Zymogenetics, Inc. | Antibodies to IL-21 receptor |
| PL1963369T3 (pl) * | 2005-11-28 | 2013-10-31 | Zymogenetics Inc | Antagoniści IL-21 |
| EP2426146B1 (en) | 2007-12-07 | 2016-02-17 | ZymoGenetics, Inc. | Anti-human IL-21 monoclonal antibodies |
-
2008
- 2008-12-08 EP EP11185989.8A patent/EP2426146B1/en active Active
- 2008-12-08 WO PCT/IB2008/005011 patent/WO2010055366A2/en not_active Ceased
- 2008-12-08 KR KR1020107014852A patent/KR101591316B1/ko active Active
- 2008-12-08 EP EP16161751.9A patent/EP3103813A1/en not_active Withdrawn
- 2008-12-08 CN CN200880126330.8A patent/CN102027011B/zh active Active
- 2008-12-08 ES ES11185989T patent/ES2572231T3/es active Active
- 2008-12-08 EP EP08878088.7A patent/EP2217268B1/en active Active
- 2008-12-08 AU AU2008364115A patent/AU2008364115B2/en active Active
- 2008-12-08 CA CA2910933A patent/CA2910933C/en active Active
- 2008-12-08 RU RU2010123049/10A patent/RU2504552C2/ru active
- 2008-12-08 HU HUE08878088A patent/HUE027828T2/en unknown
- 2008-12-08 MX MX2010006181A patent/MX2010006181A/es active IP Right Grant
- 2008-12-08 US US12/330,334 patent/US7883700B2/en active Active
- 2008-12-08 ES ES08878088.7T patent/ES2584237T3/es active Active
- 2008-12-08 CA CA2707026A patent/CA2707026C/en active Active
- 2008-12-08 JP JP2010537542A patent/JP5745274B2/ja active Active
- 2008-12-08 PL PL08878088.7T patent/PL2217268T3/pl unknown
- 2008-12-08 DK DK08878088.7T patent/DK2217268T3/en active
- 2008-12-08 KR KR1020167002415A patent/KR101615215B1/ko active Active
- 2008-12-08 CN CN201310148259.6A patent/CN103772502B/zh active Active
- 2008-12-08 BR BRPI0821168A patent/BRPI0821168B8/pt active IP Right Grant
- 2008-12-08 PT PT88780887T patent/PT2217268T/pt unknown
-
2009
- 2009-06-11 US US12/483,098 patent/US8124089B2/en active Active
-
2010
- 2010-05-26 IL IL205976A patent/IL205976A/en active IP Right Grant
- 2010-06-07 ZA ZA2010/04046A patent/ZA201004046B/en unknown
- 2010-12-17 US US12/971,495 patent/US8241629B2/en active Active
-
2012
- 2012-01-11 US US13/348,366 patent/US8226948B1/en active Active
- 2012-05-17 US US13/474,001 patent/US8361470B2/en active Active
-
2014
- 2014-02-27 JP JP2014036592A patent/JP5848384B2/ja active Active
-
2015
- 2015-07-15 IL IL239947A patent/IL239947A/en active IP Right Grant
- 2015-11-26 JP JP2015230496A patent/JP6027668B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011506422A5 (cg-RX-API-DMAC7.html) | ||
| WO2010055366A4 (en) | Anti-human il-21 monoclonal antibodies | |
| CN111171150B (zh) | 抗人tslp抗体及其用途 | |
| JP7206303B2 (ja) | 可変ドメインｖｌおよびｖｈｈ誘導体に基づく高アフィニティおよび凝集耐性抗体 | |
| JP2019162105A5 (cg-RX-API-DMAC7.html) | ||
| RU2474588C2 (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| DK2699601T3 (en) | ANTIBODY POLYPEPTIDES ANTAGONIZING CD40 | |
| AU2011237679B2 (en) | TNF-alpha binding proteins | |
| JP2010500005A5 (cg-RX-API-DMAC7.html) | ||
| RU2011116927A (ru) | Антитела против интерлейкина 17 (ил-17) человека и их применение | |
| JP2011520898A5 (cg-RX-API-DMAC7.html) | ||
| RU2011149334A (ru) | Анти-il-17f антитела и способы их применения | |
| JP2014513953A5 (cg-RX-API-DMAC7.html) | ||
| JP2015537190A5 (cg-RX-API-DMAC7.html) | ||
| CA3120102A1 (en) | Engineered cd25 polypeptides and uses thereof | |
| JP2013509158A5 (cg-RX-API-DMAC7.html) | ||
| JP6466904B2 (ja) | インターフェロンアルファ及びオメガ抗体アンタゴニスト | |
| JP7412440B2 (ja) | アビド結合多重特異性抗体を作製する方法 | |
| CN116162160A (zh) | 一种抗il-6的单域抗体及其用途 | |
| AU2015200579A1 (en) | TNF-alpha binding proteins | |
| JP2022060392A (ja) | 抗体の抗原に対する親和性を制御する方法、抗原に対する親和性が改変された抗体及びその製造方法 | |
| CN111699006B (zh) | Il17抗体及其应用 | |
| JP7691234B2 (ja) | 抗体の抗原に対する親和性を向上させる方法及びその利用 | |
| US20230391860A1 (en) | Neutralizing antibody specific to human denatured crp, and medicine and anti-inflammatory agent containing the same | |
| WO2014006230A1 (en) | Il-20 epitopes and il-20 ligands |